Defne Ercelen

Mar 6, 2024 | biorxiv.org | Kyung Ku Jang |Defne Ercelen |Chaoting Zhou |Sakteesh Gurunathan

AbstractBackground & Aims: Despite increasing therapeutic options in the treatment of ulcerative colitis (UC), achieving disease remission remains a major clinical challenge. Nonresponse to therapy is common and clinicians have little guidance in selecting the optimal therapy for an individual patient. This study examined whether patient-derived materials could predict individual clinical responsiveness to the Janus kinase (JAK) inhibitor, tofacitinib, prior to treatment initiation.